Twist Bioscience Q2 2026 earnings

What happened: Twist Bioscience Corporation (TWST) reported solid Q2 2026 financial results, marking its 13th consecutive quarter of sequential revenue growth. The company's proprietary semiconductor-based DNA platform outperformed the broader life sciences tools market. Guggenheim lifted TWST's price target from $55 to $60, citing its potential in immunology.

Market impact: The life sciences tools sector saw a boost, with TWST emerging as one of the best-performing healthcare stocks in 2026. The company's platform advantage in cost structure and consistent growth drive investor confidence. Guggenheim's price target increase signals a bullish outlook for TWST, potentially attracting more investors to the sector.

What to watch next: Twist Bioscience's Q3 2026 earnings, scheduled for August 2026, will provide insight into the sustainability of its growth trajectory. Additionally, any updates on the company's immunology pipeline and partnerships will be crucial, as Guggenheim's bullish stance is partly based on TWST's potential in this area. Lastly, broader market conditions and any regulatory changes affecting the life sciences sector may influence TWST's performance.